Innate Pharma S.A. (IPHA)
| Market Cap | 171.84M -13.6% |
| Revenue (ttm) | 10.57M -55.2% |
| Net Income | -57.74M |
| EPS | -0.65 |
| Shares Out | 93.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 633 |
| Open | 1.810 |
| Previous Close | 1.780 |
| Day's Range | 1.810 - 1.810 |
| 52-Week Range | 1.170 - 2.630 |
| Beta | 0.89 |
| Analysts | Buy |
| Price Target | 6.00 (+231.49%) |
| Earnings Date | Mar 26, 2026 |
About IPHA
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking ant... [Read more]
Financial Performance
In 2025, Innate Pharma's revenue was 9.01 million, a decrease of -55.25% compared to the previous year's 20.12 million. Losses were -49.18 million, -0.59% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for IPHA stock is "Buy." The 12-month stock price target is $6.0, which is an increase of 231.49% from the latest price.
News
Outcome of Innate Pharma's 2026 Annual General Meeting
MARSEILLE, France--(BUSINESS WIRE)--Outcome of Innate Pharma's 2026 Annual General Meeting.
Innate Pharma to participate in the Jefferies Global Healthcare Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to Participate in the Jefferies Global Healthcare Conference.
Innate Pharma Q1 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 ...
Innate Pharma Earnings Call Transcript: Q1 2026
Strong progress on three clinical assets, with lacutamab phase III and IPH4502 phase I advancing and key data readouts expected in H2 2026. AstraZeneca partnerships offer substantial milestone and royalty potential, while commercial opportunities in CTCL and urothelial cancer remain robust.
Innate Pharma Earnings release: Q1 2026
Innate Pharma released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Innate Pharma Slides: Q1 2026
Innate Pharma has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Innate Pharma Earnings release: Q1 2026
Innate Pharma released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Innate Pharma Slides: Corporate presentation
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its business update and consolidated ...
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of April 16, 2026.
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
MARSEILLE, France--(BUSINESS WIRE)---- $Innate #Biotech--Innate Pharma announces conference call and webcast for Q1 2026 Business Update.
Innate Pharma to Participate in the D. Boral Capital Global Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the D. Boral Capital Global Conference.
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that interim results from the MA...
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026
MARSEILLE, France--(BUSINESS WIRE)-- #Actionnaires--Innate Pharma to hold its annual general meeting of shareholders on May 21, 2026.
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026
MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of April 9, 2026.
Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event
MARSEILLE, France--(BUSINESS WIRE)-- #AACR--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), announced today that Yannis Morel, Chief Operating Office...
Innate Pharma to Participate in the Kempen Life Sciences Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the Kempen Life Sciences conference.
Innate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) and 2025 Form 20-f Annual Report
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) And 2025 Form 20-f Annual Report.
Innate Pharma Earnings Call Transcript: Q4 2025
Advanced three core oncology assets with strong clinical progress and regulatory milestones. Revenue reached EUR 9 million, R&D expenses fell 16% year-over-year, and cash runway extends through Q3 2026. Key late-stage trials and commercial strategies are on track.
Innate Pharma Annual report: Q4 2025
Innate Pharma has published its Q4 2025 annual report on March 26, 2026.
Innate Pharma Earnings release: Q4 2025
Innate Pharma released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Innate Pharma Earnings release: Q4 2025
Innate Pharma released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Innate Pharma Slides: Q4 2025
Innate Pharma has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 26, 2026.
Innate Pharma Annual report: Q4 2025
Innate Pharma has published its Q4 2025 annual report on March 26, 2026.
Innate Pharma Slides: Corporate presentation
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.